 Equillium, Inc. EQ, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation for itolizumab for the treatment of lupus nephritis. Equillium initiated the EQUALISE Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September 2019. The FDAs Fast Track program is designed to facilitate the development of new treatments for serious or life-threatening conditions for which there is a significant unmet medical need. 